BUZZ-AstraZeneca: FDA move makes Symbicort generics more likely - (London South East via NewsPoints Desk)

  • The FDA issued bioequivalence draft guidance for AstraZeneca's inhaled lung drug Symbicort, potentially allowing generic versions to enter the US market, as reported by London South East.
  • UBS analyst Alexandra Hauber suggested the US entry of generic versions of Symbicort this decade is now more likely.
  • She said this jeopardises the current US forecast for Symbicort sales of $1.8 billion in 2020, and estimates that in the worst case a mid-2018 generic launch could reduce valuation by 5 percent.

To read more NewsPoints articles, click here.